↑ 薬物リストへ　← 戻る

Device: novel allergen-specific immune signature directed approach to dietary elimination therapy    (DrugBank: -)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
98好酸球性消化管疾患1

98. 好酸球性消化管疾患　［臨床試験数：128，薬物数：147（DrugBank：40），標的遺伝子数：34，標的パスウェイ数：132］
Searched query = "Eosinophilic gastrointestinal disease", "Eosinophilic gastroenteritis", "Eosinophilic esophagitis", "Eosinophilic colitis", "Eosinophilic gastro-intestinal disorder", "EGID", "Neonatal food-protein induced enterocolitis", "N-FPIES"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 128 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02722148
(ClinicalTrials.gov)		April 21, 201624/3/2016Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)Eosinophilic EsophagitisDevice: Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination TherapyUniversity of North Carolina, Chapel HillNational Institutes of Health (NIH)Completed16 Years80 YearsAll24N/AUnited States